XML 43 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborations and Other Arrangements (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2014
Oct. 31, 2013
Dec. 31, 2009
Jun. 30, 2001
Sep. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Mar. 31, 2015
Jun. 30, 2011
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Oct. 01, 2015
Collaboration and other revenue         $ 216.5     $ 215.2     $ 607.3 $ 644.7    
Revenue         5,191.7     4,959.7     15,461.6 14,583.1    
Research and development         1,236.4     1,143.4     3,793.3 3,352.2    
Nonoperating Income (Expense)         27.2     86.5     (100.6) 55.9    
Marketing, selling, and administrative         1,565.4     1,575.7     4,661.9 4,734.6    
Acquired in-process research and development         0.0     0.0     0.0 336.0    
Tanezumab [Member]                            
Acquired in-process research and development                 $ 200.0          
Sales [Member] | Erbitux [Member]                            
Collaborative Arrangement, Rights and Obligations Percent             38.00%              
Profit and Development and Marketing Share [Member] | Effient [Member]                            
Collaborative Arrangement, Rights and Obligations Percent       50.00%                    
Research and Development Exp [Member] | Baricitinib [Member]                            
Collaborative Arrangement, Rights and Obligations Percent     30.00%                      
Milestone Payments, Development and Regulatory, Capitalized [Member] | Lly Compounds [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms [1],[2]                     187.5   $ 0.0  
Milestone Payments, Development and Regulatory, Capitalized [Member] | Trajenta (BI) [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms [1],[3]                     0.0   0.0  
Milestone Payments, Development and Regulatory, Capitalized [Member] | Jardiance (BI) [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms [1],[4]                     0.0   $ 0.0  
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Lly Compounds [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms [1],[2],[5]                     250.0      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Trajenta (BI) [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms [1],[3],[5]                     (446.4)      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Jardiance (BI) [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms [1],[4],[5]                     (299.5)      
Milestone Payments, Development and Regulatory, Expensed [Member] | Baricitinib [Member]                            
Research and development           $ 55.0                
Milestone Payments, Sales-based [Member] | Solanezumab [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms                   $ (70.2)        
Milestone Payments, Sales-based [Member] | Baricitinib [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms     $ (150.0)                      
Milestone Payments, Sales-based [Member] | Tanezumab [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms   $ (1,230.0)                        
Milestone Payments, Development and Regulatory [Member] | Lly Compounds [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms           $ 187.5                
Milestone Payments, Development and Regulatory [Member] | Baricitinib [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms     (360.0)                      
Milestone Payments, Development and Regulatory [Member] | Tanezumab [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms   $ (350.0)                        
Milestone Payments, Development and Regulatory [Member] | BACE Inhibitor [Member]                            
Research and development         100.0                  
Collaborative Arrangement, Rights and Obligations, Terms $ (350.0)                          
Milestone Payments, Development and Regulatory, First Indication [Member] | Baricitinib [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms     $ (180.0)                      
Royalty Agreement Terms [Member] | Solanezumab [Member]                            
Collaborative Arrangement, Rights and Obligations, Terms of Arrangement, Period                   10 years        
Royalty Agreement Terms [Member] | Baricitinib [Member]                            
Collaborative Arrangement, Rights and Obligations Percent     20.00%                      
Upfront Payment [Member] | Tanezumab [Member]                            
Acquired in-process research and development                 $ 200.0          
Collaborative Arrangement [Member]                            
Marketing, selling, and administrative         47.4     53.6     143.7 156.5    
Human Pharmaceutical Products [Member]                            
Revenue         4,485.5     4,180.9     13,141.1 12,213.8    
Human Pharmaceutical Products [Member] | Erbitux API [Member]                            
Sales Revenue, Goods, Net         0.0     (2.3)     0.0 22.6    
Human Pharmaceutical Products [Member] | Erbitux [Member]                            
Collaboration and other revenue         28.7     88.2     77.5 286.2    
Revenue         184.6     85.9     533.3 308.8    
Sales Revenue, Goods, Net         155.9     0.0     455.8 0.0    
Human Pharmaceutical Products [Member] | Effient [Member]                            
Revenue         127.7     132.1     394.3 382.7    
Human Pharmaceutical Products [Member] | Trajenta (BI) [Member]                            
Collaboration and other revenue         115.4     92.7     330.8 255.0    
Human Pharmaceutical Products [Member] | Jardiance (BI) [Member]                            
Collaboration and other revenue         $ 47.5     15.4     $ 125.8 45.7    
Erbitux Acquisition [Member]                            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles [6]                           $ 602.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory                           232.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent                           (228.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets                           57.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net                           663.3
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability [7]                           $ (663.3)
Business Acquisition, Pro Forma Revenue               5,000.0       14,800.0    
Erbitux Acquisition [Member] | Erbitux [Member]                            
Business Acquisition, Pro Forma Revenue               $ 150.0       $ 560.0    
[1] (1) In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.
[2] (4) In September 2015, we entered into a settlement agreement to resolve patent infringement litigation filed by Sanofi-Aventis U.S. LLC, which markets Lantus® (insulin glargine). As part of the settlement agreement, the parties agreed that Basaglar can be launched in the U.S. beginning on December 15, 2016. Basaglar received U.S. Food and Drug Administration (FDA) approval in December 2015. As a result of receiving FDA approval, we received a $187.5 million milestone payment from Boehringer Ingelheim in the first quarter of 2016, which was recorded as deferred revenue and, upon product launch, will be amortized through the term of the collaboration to collaboration and other revenue.
[3] (2) Jentadueto is included in the Trajenta family of product results.
[4] (3) Glyxambi and Synjardy are included in the Jardiance family of product results.
[5] (5) The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration.
[6] (1) These intangible assets are being amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018.
[7] (2) See Note 6 for discussion on the estimation of the contingent consideration liability.